Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension

Genetic Testing and Molecular Biomarkers

Volumn 19, Issue 3, 2015, Pages 124-127

  Wang, Xiang Sheng ^a   Yang, Wen ^b   Luo, Tong ^a   Wang, Jian Ming ^a   Jing, Yan Yan ^b  

^a Department of Urology   (China)

^b QINGDAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ENDOCAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEOGLYCAN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; ESM1 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; ARTICLE; BODY MASS; CARDIAC PATIENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; MIDDLE AGED;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTEOGLYCANS;

EID: 84924372115     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2014.0274     Document Type: Article

References (13)

1. Balci DD, Balci A, Karazincir S, et al. (2009) Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol 23:1-6.
2. Balta I, Balta S, Demirkol S, et al. (2013) Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol 169:1066-1070.
3. Balta S, Mikhailidis DP, Demirkol S, et al. (2014) Endocan-A novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology 65:773-777.
4. Bechard D, Meignin V, Scherpereel A, et al. (2000) Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 37:417-425.
5. Dalekos GN, Elisaf MS, Papagalanis N, et al. (2000) Elevated interleukin-1 beta in the circulation of patients with essential hypertension before any drug therapy: a pilot study. Eur J Clin Invest 26:936-939.
6. Fang C, Lei J, Zhou SX, et al. (2013) Association of higher resistin levels with inflammatory activation and endothelial dysfunction in patients with essential hypertension. Chin Med J (Engl) 126:646-649.
7. Lassalle P, Molet S, Janin A, et al. (1996) ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 271:20458-20464.
8. Ozaki K, Toshikuni N, George J, et al. (2014) Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma. J Cancer 5:221-230.
9. Sarrazin S, Adam E, Lyon M, et al. (2006) Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 1765:25-37.
10. Scherpereel A, Depontieu F, Grigoriu B, et al. (2006) Endocan, a new endothelial marker in human sepsis. Crit Care Med 34:532-537.
11. Tatami R, Mabuchi H, Ueda K, et al. (1981) Intermediatedensity lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation 64:1174-1184.
12. Yang R, Yu J (2014) Evaluation of the associations between vascular endothelial function and coronary artery stenosis in patients with elevated blood pressure during coronary angiography. Heart Surg Forum 17:E150-E153.
13. Zhao ZW, Lin CG, Wu LZ, et al. (2013) Serum fetuin-A levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes. Biomarkers 18: 160-164.